Thermo Fisher Scientific Prices Offering of Senior Notes

WALTHAM, Mass.--()--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has priced its previously announced offering of senior notes, consisting of:

  • $900 million aggregate principal amount of 1.30% senior notes due 2017 at an issue price of 99.941% of the principal amount,
  • $900 million aggregate principal amount of 2.40% senior notes due 2019 at an issue price of 99.796% of the principal amount,
  • $1 billion aggregate principal amount of 4.15% senior notes due 2024 at an issue price of 99.73% of the principal amount, and
  • $400 million aggregate principal amount of 5.30% senior notes due 2044 at an issue price of 99.928% of the principal amount.

The issuance of the notes is expected to close on December 11, 2013, subject to customary closing conditions. The notes will pay interest on a semi-annual basis.

The company plans to use the proceeds of the offering to fund a portion of its acquisition of Life Technologies Corporation. On April 15, 2013, the company announced its agreement to acquire Life Technologies for an aggregate purchase price of approximately $13.6 billion.

The joint book-running managers for the offering are Barclays Capital Inc., J.P. Morgan Securities LLC and RBS Securities Inc.

Thermo Fisher has filed a registration statement on Form S-3 (including a prospectus) with the Securities and Exchange Commission (the “SEC”) for this offering. Prospective investors should read the prospectus forming a part of that registration statement and the prospectus supplement related to the offering and the other documents that the company has filed with the SEC for more complete information about the company and this offering. These documents are available at no charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, these documents will be made available upon request by the company or by any joint book-running manager for the offering. Interested parties may obtain a prospectus or the related preliminary prospectus supplement from Barclays Capital Inc. by directing a request to Barclays Capital Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by writing barclaysprospectus@broadridge.com or by calling 1-888-603-5847; from J.P. Morgan Securities LLC by directing a request to J.P. Morgan Securities LLC, 383 Madison Avenue, New York, NY 10179, Attn: Investment Grade Syndicate Desk - 3rd Floor, or by calling 212-834-4533; or from RBS Securities Inc. by directing a request to RBS Securities Inc., 600 Washington Boulevard, Stamford, CT 06901, Attn: Syndicate, or by calling 866-884-2071.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes, nor shall there be any offer, solicitation or sale of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

Contacts

Thermo Fisher Scientific Inc.
Media Contact Information:
Ron O’Brien, 781-622-1242
ron.obrien@thermofisher.com
or
Investor Contact Information:
Ken Apicerno, 781-622-1294
ken.apicerno@thermofisher.com
www.thermofisher.com

Sharing

Contacts

Thermo Fisher Scientific Inc.
Media Contact Information:
Ron O’Brien, 781-622-1242
ron.obrien@thermofisher.com
or
Investor Contact Information:
Ken Apicerno, 781-622-1294
ken.apicerno@thermofisher.com
www.thermofisher.com